| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-05-10 | Axxam (Italy) MD Anderson Cancer Center (USA - TX) | small molecule modulators of an undisclosed G-protein coupled receptor | Alzheimer's disease | R&D |
Neurodegenerative diseases | R&D agreement |
| 2016-05-10 | Bayer Healthcare (Germany) Biontech (Germany) | mRNA vaccines and therapeutics | development |
Veterinary medicine | Development agreement | |
| 2016-05-10 | PEP Therapy (France) | nomination |
Nomination | |||
| 2016-05-10 | Opko Health (USA - Fl) | nomination |
Nomination | |||
| 2016-05-10 | Confo Therapeutics (Belgium) | nomination |
Nomination | |||
| 2016-05-10 | JHL Biotech (Taiwan) | biopharmaceutical manufacturing facility in Wuhan | opening of new premises |
Technology - Services | Opening of new premises | |
| 2016-05-10 | Achaogen (USA - CA) Crystal Bioscience (USA - CA) | monoclonal antibodies against multiple targets | R&D - research - licensing | Infectious diseases | Research agreement | |
| 2016-05-09 | Fujifilm Diosynth Biotechnologies (USA - NC) | Technology - Services | Opening of new premises | |||
| 2016-05-09 | Arsanis (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2016-05-09 | Epizyme (USA - MA) Lymphoma Study Association (LYSA) (France) | tazemetostat - EPZ-6438 (E7438) with R-CHOP | diffuse large B-cell lymphoma (DLBCL) | collaboration clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-05-09 | Opko Health (USA - Fl) Vifor Fresenius Medical Care Renal Pharma (Germany) | Rayaldee™ (calcifediol - vitamin D prohormone) | secondary hyperparathyroidism in patients with chronic kidney disease (CKD) and vitamin D insufficiency | collaboration licensing commercialisation |
Hormonal diseases - Endocrine diseases - Renal diseases - Kidney diseases | Licensing agreement |
| 2016-05-09 | Epirus Biopharmaceuticals (USA - MA) | restructuring
|
Restructuring | |||
| 2016-05-06 | Epizyme (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-05-06 | Alder Biopharmaceuticals (USA - WA) Vitaeris (Canada) | clazakizumab | inflammatory diseases | licensing | Inflammatory diseases | Licensing agreement |
| 2016-05-05 | Nuevolution (Denmark) | nomination |
Inflammatory diseases | Nomination | ||
| 2016-05-05 | Bind Therapeutics (USA - MA) Affilogics (France) | Accurins® designed to bind immuno-oncology targets | R&D collaboration |
Cancer - Oncology | R&D agreement | |
| 2016-05-05 | Valeant Pharmaceuticals (Canada) Bausch&Lomb (USA) IBM (USA) | app for iPhone and iPad to assist surgeons who perform cataract surgery | Cataracts | collaboration |
Ophtalmological diseases | Collaboration agreement |
| 2016-05-04 | Audentes Therapeutics (USA - CA) Regenx Biosciences (USA - MD) | NAV rAAV8 and rAAV9 vectors | X-Linked Myotubular Myopathy (XLMTM), Pompe disease | licensing development commercialisation |
Rare diseases - Genetic diseases | Licensing agreement |
| 2016-05-04 | Audentes Therapeutics (USA - CA) Perelman School of Medicine at the University of Pennsylvania (USA - PA) | AT342 | Crigler-Najjar Syndrome | R&D |
Rare diseases - Genetic diseases - Hepatic diseases - Liver diseases | R&D agreement |
| 2016-05-04 | Tiziana Life Sciences (UK) | nomination |
Nomination |
